Filana Therapeutics, Inc. (FLNA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Filana Therapeutics, Inc. (FLNA) has a cash flow conversion efficiency ratio of -0.131x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.75 Million) by net assets ($74.40 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Filana Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Filana Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Filana Therapeutics, Inc. for a breakdown of total debt and financial obligations.
Filana Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Filana Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Abeo SAS
PA:ABEO
|
-0.050x |
|
Falcon Metals Ltd
AU:FAL
|
-0.027x |
|
ANDRADA MINING LTD.
F:9IA
|
N/A |
|
AEC SECURITIES
BK:BYD-R
|
N/A |
|
SAMRYOONG Co.Ltd
KQ:014970
|
0.052x |
|
Bilici Yatirim Sanayi ve Ticaret AS
IS:BLCYT
|
-0.021x |
|
SANU GOLD CORP.
F:L73
|
N/A |
|
DCM Corp
KO:024090
|
0.019x |
Annual Cash Flow Conversion Efficiency for Filana Therapeutics, Inc. (2022–2025)
The table below shows the annual cash flow conversion efficiency of Filana Therapeutics, Inc. from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see FLNA company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $74.40 Million | $-32.25 Million | -0.433x | +45.98% |
| 2024-12-31 | $145.70 Million | $-116.93 Million | -0.803x | -34.49% |
| 2023-12-31 | $137.47 Million | $-82.03 Million | -0.597x | -75.15% |
| 2022-12-31 | $227.54 Million | $-77.51 Million | -0.341x | -- |
About Filana Therapeutics, Inc.
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from… Read more